Author

Mohamed A. Aboelatta

Observed names: M. Aboelatta, Mohamed Aboelatta

Institution: Mayo Clinic

Observed institutions: Mayo Clinic, King Fahad Specialist Hospital

ORCID: 0009-0002-3038-0780

Observed ORCID: 0009-0002-3038-0780

OpenAlex ID: A5128816166

Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective study

2025 · Mohamed Aseafan, Ali H. Alfakeeh, et al. · BMC Cancer · 7

CD4 T-cell reconstitution and CD4:CD8 inversion following lymphodepleting chemotherapy for tumor-infiltrating lymphocyte therapy in metastatic melanoma.

2026 · Arkadiusz Z. Dudek, Mohamed A. Aboelatta, et al. · Journal of Clinical Oncology · 1

Outcomes and prognostic factors in melanoma patients with leptomeningeal disease: a retrospective cohort study

2026 · Mohamed A. Aboelatta, Ali Rezazadeh, et al. · Melanoma Research · 1

Immune Checkpoint Inhibitor Therapy of Malignancy in Kidney Transplant Recipients: Analysis of Real-world Outcomes

2026 · Ali Rezazadeh, Elena-Bianca Barbir, et al. · Transplantation Direct

Real-World Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Treatment Delivery, Immune Reconstitution, and Cardiac Monitoring During High-Dose IL-2

2026 · Mohamed A. Aboelatta, Jabra Zarka, et al. · Current Oncology

Clinicopathologic Findings in Immune Checkpoint Inhibitor Associated Renal Allograft Rejection

2026 · C. Haivas, E. Barbir, et al. · American Journal of Transplantation

Influence of peri-dose high-sensitivity troponin on clinically significant cardiac events and IL-2 interruption during post-TIL high-dose IL-2 therapy.

2026 · Jabra Zarka, Mohamed A. Aboelatta, et al. · Journal of Clinical Oncology

Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma.

2026 · Alexandra Haugh, Mohamed A. Aboelatta, et al. · Journal of Clinical Oncology

Baseline visceral disease burden and treatment delivery factors association with outcomes after tumor-infiltrating lymphocyte therapy for metastatic melanoma.

2026 · Mohamed A. Aboelatta, Jabra Zarka, et al. · Journal of Clinical Oncology

Abstract 6544: Immune checkpoint inhibitor therapy in kidney transplant recipients: Real-world outcomes of antitumor activity and graft rejection risk

2026 · Ali Rezazadeh Roudkoli, Elena Barbir, et al. · Cancer Research

Abstract 3706: Impact of number of IL-2 infusions and product out of specification status on outcomes of tumor infiltrating lymphocyte therapy for melanoma

2026 · Mohamed A. Aboelatta, Jeffrey E. Johnson, et al. · Cancer Research

Works count: 11

Citation count: 9

H-index: 1

I10-index: